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ThromboembolismAbstract Background: Over 50 years the research work all over the world was concerning to ﬁnd
out a novel oral heparin to avoid the side effects of conventional anticoagulants as warfarin which
requires changes in diet and lifestyle, regular checkup, and has a risk of severe hemorrhage.
Rivaroxaban offers such advantages as oral mode of administration, more predictable anticoagu-
lant response, greater speciﬁcity with no need for routine checkup and patient monitoring and
has a uniform dose. When switching patients from warfarin to rivaroxaban, warfarin is discontin-
ued and rivaroxaban is started as soon as INR is below 3.0 to avoid periods of inadequate antico-
agulation.
Aim of the work: To study the role and suitability of oral rivaroxaban therapy in management of
venous thromboembolism in Egyptian patients.
Patient and methods: This work was done over 120 mild or minor pulmonary embolism patients,
divided into 2 groups, group I included 100 patients received oral rivaroxaban for 1 week, continued
with warfarin for 6 months guided with INR measurement, group II included 20 patients who are
ﬁnancially supported and can continue with rivaroxaban for 6 months. The following was done for
all patients. Clotting time (CT), D Dimer, INR, APTT, platelet count, complete liver and kidney
functions, digital X ray Chest, multi-slice CT angiogram in some cases, and ECG, CK MB and tro-
ponin when needed.
Results: Our patients were divided into 2 groups, group I included 100 patients 54 males and 46
females with a mean age of 48.3 ± 15.43 and a mean body weight of 84.7 ± 16.4 group II included
20 patients 11 males and 9 females with a mean age of 45.6 ± 12.21and a mean body weight of
85.2 ± 12, the recorded side effects were minor bleeding in 11% of the cases of group I and
10% of the cases of group II, headache in 6% of the cases of group I and 5% of the cases of group
II, GIT upset in 5% of the cases in both groups, dizziness in 4% of the cases of group I and 5% of
the cases of group II with no statistical signiﬁcant differences between the 2 arms of the study.rculosis.
894 M. Abdalwahab et al.Conclusion and recommendation: Rivaroxaban is a rapid onset of anticoagulant that can be given
in ﬁxed doses without routine monitoring. It can replace injectable anticoagulants as an initial treat-
ment in management of patients with mild venous thromboembolism as it is suitable as regard the
economic and the health status of the Egyptian patients.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
There is a clinical need for safe new oral anticoagulants, as the
currently available anticoagulants such as vitamin K antago-
nists [1] and low-molecular-weight heparins (LMWHs) [2],
are not targeted, which means that they inhibit more than
one enzyme in the coagulation cascade. In recent years, new
anticoagulants targeting single component of the coagulation
cascade have been developed.
The use of warfarin reduces the rate of thromboembolic
stroke in patients with atrial ﬁbrillation but requires frequent
monitoring and dose adjustment as its response is modiﬁed
by genetic and environmental factors that can inﬂuence its
absorption, pharmacokinetics, and pharmacodynamics.
Rivaroxaban, is the ﬁrst bioavailable orally administered
direct factor Xa inhibitor, which may provide more consistent
and predictable anticoagulation than warfarin [3], as it selec-
tively and reversibly blocks the active site of factor Xa and
does not require a cofactor (such as Anti-thrombin III) for
activity. Activation of factor X plays a central role in the coag-
ulation cascade. As factor Xa acts at the junction of the exter-
nal and internal pathways of coagulation, rivaroxaban
prolongs both PT and aPTT, which is dose dependent [4].
Rivaroxaban maximum plasma concentration is 30 min to
3 h, and its half-life has been reported to be 3–9 h.
Rivaroxaban provides high potency and selectivity and dose-
dependent inhibition of factor Xa. Two thirds of the drug is
metabolized to inactive metabolites in liver, half of which is
excreted by kidneys and other half is excreted via fecal route.
CYP3A4, CYP345, and CYP2J2 catalyze the hepatic metabo-
lism of rivaroxaban [5]. The other one-third is excreted
unchanged by kidneys. As a signiﬁcant portion of rivaroxaban
is excreted via kidneys, renal impairment is expected to increase
the concentration of the drug, with increasing severity of renal
impairment causing more retention of the drug. Mild renal
impairment (creatinine clearance 50–80 mL/min) increases the
concentration (AUC) of the drug by 44%,moderate impairment
(Cr CL 30–49 mL/min) by 52%, and severe impairment (Cr CL
15–29 ml/min) by 64% that is associatedwithmore inhibition of
factor Xa andmore prolongation of PT. The drug is contraindi-
cated in patients with severe renal impairment with
CrCl < 15 mL/min to avoid excessive drug accumulation and
bleeding [6], liver impairment (dabigatran does not undergo
hepatic metabolism andmay be safe in patients with hepatic dis-
ease), as well as those who are pregnant (category C drug),
breastfeeding should not take rivaroxaban [7].
Aim of the work
To study the role and suitability of oral rivaroxaban therapy in
management of venous thromboembolism in Egyptian patients.Methodology
This work was done in Chest department, Tanta University,
Egypt from March 2012 to December 2013 over 120 mild or
minor pulmonary embolism patients divided into 2 groups,
group I included 100 patients who received oral rivaroxaban
for 7 days, in a dose 10–20 mg twice daily according to the
hepatic and renal status of the patient, warfarin was added
from the third day, after 1 week rivaroxaban was withdrawn,
and warfarin continued for 6 months guided with INR mea-
surement. Initial INR was done before starting warfarin, then
repeated after 1 week, 2 weeks and then monthly to adjust war-
farin dosage, group II included 20 patients who are ﬁnancially
supported and can continue with rivaroxaban for 6 months.
The following was done for all patients: Thorough history tak-
ing, complete physical examination, clotting time (CT), D
Dimer, INR, APTT, platelet count, urea and creatinine,
SGPT, SGOT, direct and indirect serum bilirubin, digital X
ray Chest P/A and lateral view, multi-slice CT angiogram in
some cases, and ECG, CK MB and troponin when
needed.Inclusion criteria were patients with mild or minor pul-
monary embolism, haemodynamically stable, with normal O2
saturation, refusing hospitalization. Exclusion criteria were
patients with recent or known bleeding disorders, severe
heart-valve disorder, stroke within 14 days or severe stroke
within 6 months, uncontrolled hypertension, severe renal dys-
function with creatinine clearance < 30 ml/min, recent gas-
trointestinal bleeding due to ulceration or esophageal varices,
active liver disease and pregnancy or breast-feeding.
Results
This work was done over 120 mild or minor PE patients,
divided into 2 groups, group I included 100 patients 54
males and 46 females with a mean age of 48.3 ± 15.43
and a mean body weight of 84.7 ± 16.4 group II included
20 patients 11 males and 9 females with a mean age of
45.6 ± 12.21 and a mean body weight of 85.2 ± 12 .The
main symptoms of our patients were dyspnea in 74.1%,
chest pain in 65%, haemoptysis in 33.3%, cough in 19%
and wheeze in 15%, the main risk factors for VTE were
obesity in 51.6% dyslipidemia in 49.1%, smoking in
26.6%, hormonal contraceptives in 25.8% DM in 24.1%,
hyper-tension in 18.3%, hypervitaminosis k in 16.6% and
other cardiac disorder in 15%, the recorded side effects were
minor bleeding in 11% of the cases of group I and 10% of
the cases of group II, headache in 6% of the cases of group
I and 5% of the cases of group II, GIT upset in 5% of the
cases in both groups, dizziness in 4% of the cases of group I
and 5% of the cases of group II with no statistical signiﬁ-
cant differences between the 2 arms of the study.
Table 1 Some demographic data of studied groups (Age, Sex
and Body weight).
Parameters Group I Group II P
Age 48.3 ± 15.43 45.6 ± 12.21 NS
Sex Male 54/100 (54%) 11/20 (55%) NS
Female 46/100 (46%) 9/20 (45%) NS
Body weight 84.7 ± 16.4 85.2 ± 12 NS
Table 2 Symptoms of PE in the studied patients.
+VE No %
Dyspnea 89 74.1
Chest pain 78 65.0
Haemoptysis 40 33.3
Cough 23 19.1
Wheeze 19 15.8
Table 3 Risk factors of pulmonary embolism of studied
patients.
+VE No %
Obesity 62 51.6
Dyslipidemia 59 49.1
SMOKING 32 26.6
CONTRACEPTIVE 31 25.8
DM 29 24.1
HTN 22 18.3
HYPERVITAMINOSIS K 20 16.6
Other cardiac disorders 18 15
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Figure 1 Risk factors of pulmonary embolism.
Table 4 Statistical comparison of the side effects of warfarin
(group I) against rivaroxaban (group II).
Side eﬀects Group I Group II P
Minor bleeding 11/100 (11%) 2/20 (10%) NS
Headache 6/100 (6%) 1/20 (5%) NS
GIT upset 5/100 (5%) 1/20 (5%) NS
Dizziness 4/100 (4%) 1/20 (5%) NS
Side effects of warfaren (Group I) against rivaroxaban 
(Group II)
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Figure 2 Side effects of warfarin (group I) against rivaroxaban
(group II).
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the side effects in both arms of the study (Tables 1–3, Fig. 1,
Table 4 and Fig. 2).Discussion
Since the 1950s, the VKA warfarin has been the gold standard
in VTE treatment [8]. However, a slow onset of action, a nar-
row therapeutic range and variable pharmaco-kinetics (leading
to unpredictable anticoagulation) make the use of warfarin
challenging. Multiple food and drug interactions, dietary
intake of vitamin K and genetic polymorphisms contribute
to variability in the effects of warfarin. [8,9] As a result, there
is a need for frequent coagulation monitoring and dose adjust-
ment to maintain treatment within the therapeutic range
[10,11]. Insufﬁcient anticoagulation may lead to recurrent
VTE, whereas excessive anticoagulation may place patients
at a higher bleeding risk. [8] The onset of action of warfarin
takes 36–72 h therefore, there is a need for initial bridging ther-
apy with a fast-acting parenteral agent such as unfractionated
heparin (UFH), low molecular weight heparin (LMWH) for a
minimum of 5 days [12,13] VKA therapy may begin on the ﬁrst
or second day of parenteral therapy and requires close INR
monitoring, which should be 2.0–3.0 (target 2.5) for P24 h
(North American guidelines) or for 2 consecutive days
(European guidelines) before discontinuation of the parenteral
agent [10,11]. Management of classical anticoagulants in
elderly patients is challenging, due to age-related physiological
changes, likelihood of co-morbidities and concomitant medica-
tions, and the increased risk of adverse events coupled with the
potential difﬁculty for older patients to attend clinics regularly
for INR monitoring, poor anticoagulation control with the
classical dual-drug approach is likely [14]. Rivaroxaban is a
long-awaited appealing agent because it is easy to use, does
not require laboratory monitoring, and has demonstrated
equivalence, or in some cases, superiority to warfarin in pre-
venting stroke or systemic embolism in at-risk population [15].
Rivaroxaban is, at present the only one of the new oral
anticoagulants that is FDA approved for the treatment of
DVT and PE. It is also approved as a prophylaxis of DVT
and PE after hip and knee replacement surgery, and also as
a prophylaxis of stroke and other thrombo-embolic manifesta-
tions in patients with AF [16,17].
Minor side effects include headache, hypotension, dizziness,
tachycardia, vomiting, edema; people who took a higher dose
896 M. Abdalwahab et al.were more likely to suffer from bleeding. Also patients who
suddenly stop taking rivaroxaban can be at increased risk for
developing thromboembolic disorders. One of the most serious
side effects of rivaroxaban is bleeding and anemia, reduced
platelet levels, abnormal liver function. Concomitant use of
drugs affecting coagulation (eg, platelet aggregation inhibitors,
other antithrombotic agents, ﬁbrinolytic therapy) can increase
the risk of bleeding [12].
Recombinant, modiﬁed factor Xa molecule is being devel-
oped as a direct reversal agent (antidote) for patients receiving
a Factor Xa inhibitor who suffer a major bleeding episode or
who require emergency surgery. It stops the activity of anti-Xa
anticoagulant, making a patient’s own factor Xa available
again to participate in the coagulation process [18].
Conclusion and recommendation
Rivaroxaban has a rapid onset of anticoagulant activity, with
a low potential for interactions with diet and other drugs. It
can be given in ﬁxed doses and does not require routine mon-
itoring. It can replace injectable anticoagulants as an initial
treatment in management of patients with mild venous throm-
boembolism as it is suitable as regard the economic and the
health status for the Egyptian patients.
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